CRNX - Latest News

Crinetics Pharmaceuticals, Inc. (CRNX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $9.01B. Beta to the broader market is 0.13.

The article list below shows the most recent CRNX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent CRNX Headlines

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

etftrends.com - Oct 12, 2026

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest i

Financial Comparison: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lyra Therapeutics (OTCMKTS:LYRA)

defenseworld.net - Sep 21, 2026

Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both healthcare companies, but w

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

fool.com - Sep 10, 2026

FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

businesswire.com - Sep 1, 2026

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics

BlackRock Inc. Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNX

defenseworld.net - Aug 26, 2026

BlackRock Inc. purchased a new position in shares of Crinetics Pharmaceuticals, Inc.

How News Affects CRNX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CRNX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.